+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

The Corporate Reputation of Pharma in 2019 - The Patient Perspective - Cancer Edition - The Views of 389 Cancer Patient Groups

  • ID: 5129259
  • Report
  • May 2020
  • Region: Global
  • 40 Pages
  • PatientView
1 of 4
What 389 Cancer Patient Groups Think of 33 Pharma Companies in 2019

FEATURED COMPANIES

  • AbbVie
  • Boehringer Ingelheim
  • Eli Lilly
  • Ipsen
  • Merck KGaA/EMD Serono
  • Pierre Fabre
  • MORE

This is the 8th edition of 'The Corporate Reputation of Pharma - from the Perspective of Cancer Patient Groups'. The 2019 results are drawn from a survey of cancer patient groups, conducted November 2019 - February 2020.

About the 2019 Survey of Cancer Patient Groups

25% of 2019’s respondent cancer patient groups were umbrella patient groups, and/or covered most types of cancer. The remainder specialised in various types of cancer.

The 389 cancer patient groups came from 57 countries, with the following geographic remits: 68% had a national geographic remit; 11% an international remit; 11% regional (an area within one country); and 11% were local.

On cancer patient-group relationships with pharma

  • 78% of the 389 cancer patient groups responding to the 2019 survey worked with at least one pharma company.

The analyst also provides 2019 performance indicators on companies, as judged by respondent cancer patient groups from six different cancer specialties:

  • Blood cancers [58 blood-cancer patient groups examine 19 companies that produce blood-cancer treatments].
  • Breast cancer [75 breast-cancer patient groups examine 20 companies].
  • Lung cancer [29 patient groups examine 13 companies].
  • Ovarian cancer [22 patient groups examine 6 companies].
  • Prostate cancer [24 patient groups examine 6 companies].
  • Rare cancers [25 patient groups examine 5 companies].

What this Report Contains

Industry-wide analyses: The report examines the issues of importance to cancer patient groups, including: levels of industry innovation; access to treatments; transparency of the industry; and drug pricing. Analyses are reinforced by extensive feedback from 2019's respondent cancer patient groups, classified in a 54-page Appendix according to the specialties of the respondent patient groups.

Individual company analyses: The 33 pharma companies are reviewed by 2019's 389 respondent cancer patient groups for overall corporate reputation, and for performance at 12 individual indicators of corporate reputation.

Key Industry-Wide Findings:

2019’s industry-wide ‘Corporate-Reputation’ cancer results can largely be explained by the scale of industry’s endeavour in each cancer therapy area - specifically, the range of treatments available - as perceived by the various types of cancer patient groups. Cancer patient groups specialising in the more well-established cancer therapy areas (such as blood, breast, or lung cancer) tend to score the pharma industry higher for corporate reputation.

For example, while 68% of 2019’s 29 respondent lung-cancer patient groups thought that the pharma industry had an “Excellent or “Good” corporate reputation, only 33% of 2019’s 24 respondents prostate-cancer patient groups.

On transparency: A few of 2019’s respondent cancer patient groups acknowledged the role that national pharmaceutical trades-bodies have played in setting transparency standards, alongside regulators. Pockets of best practice were separately mentioned by three respondent cancer patient groups (one from Australia, one from Bulgaria, and one from Finland). However, as in previous years (and in common with patient groups in non-cancer therapy areas), most of 2019’s respondent cancer patient groups rated the industry low for transparency - with only around one fifth calling the industry “Excellent” or “Good” at the three elements of transparency measured by the survey.

On pricing: Recent tremendous advances in oncology treatments have come with a high price tag. Treatments are often used in combination, multiplying the cost to patients for a course of treatment offering months of life. National Health Technology Assessment (HTA) authorities have found it difficult to demonstrate cost effectiveness, which has led to much negotiation over confidential discounts on a per-nation basis. Not surprisingly, only 10% of 2019’s respondents 389 cancer patient groups thought the pharmaceutical industry “Excellent” or “Good” at setting fair pricing policies. This percentage has been slowly sliding since 2013 when it stood at 16%. One of the key pricing issues highlighted by feedback from 2019’s respondent cancer patient groups is differential pricing systems for drugs, country to country - information about which should be in the public domain, say respondent cancer patient groups.

Key Company Findings:

Four major pharmaceutical companies continue to dominate the cancer league tables for 2019: Janssen, Novartis, Pfizer, and Roche/Genentech.

  • Ranked 1st: Roche/Genentech was ranked overall 1st out of 33 companies for corporate reputation in 2019 by the 312 respondent cancer patient groups familiar with the company. In 2018, Roche was ranked 3rd out of 36 companies by the cancer patient groups familiar with it. Roche was also ranked 1st in 2019 for all 12 indicators of corporate reputation, among both patient groups that were familiar with the company, and those that worked with it.
  • Ranked 2nd: Novartis was ranked overall 2nd out of 33 companies for corporate reputation in 2019 by the 325 respondent cancer patient groups familiar with the company. In 2018, Novartis was ranked 2nd out of 36 companies by the cancer patient groups familiar with it.
  • Ranked 3rd: Pfizer was ranked overall 3rd out of 33 companies for corporate reputation in 2019 by the 306 respondent cancer patient groups familiar with the company. In 2018, Pfizer was ranked 4th out of 36 companies by the cancer patient groups familiar with it.
  • Ranked 4th: Janssen was ranked overall 4th out of 33 companies for corporate reputation in 2019 by the 215 cancer patient groups familiar with the company. In 2018, the company was ranked 1st out of 36 companies by the cancer patient groups familiar with it.

Other success stories in the cancer results

  • Daiichi Sankyo was first included in the cancer analyses in 2018 when the company was ranked 34th among patient groups familiar with it. In 2019, Daiichi rose 12 places, to reach overall 22nd.
  • Servier continued to see big improvements in its corporate reputation among cancer patient groups familiar with the company, rising from 28th position in 2017 to 17th in 2018, and, again, reaching overall 10th in 2019.
  • Takeda/Shire maintained a position in the cancer top ten in 2019, ranking overall 8th among cancer patient groups familiar with the company. In 2018, the company had seen a meteoric rise up the cancer Corporate-Reputation rankings, when it jumped 15 places from overall 20th in 2017 to overall 5th in 2018.

A note about COVID-19 and this study's results

Covid-19 should have a relatively limited impact on many of the results of the 2019 ‘Corporate-Reputation’ study, because the survey took place (November 2019 to late-February 2020) largely before the crisis became global. However, the opinions of the 3 respondent China-based cancer patient groups may have been influenced by the epidemic. Announcements about Covid-19 by some pharma companies during January and February 2020, and reported in the US media, may have influenced the views of the 67 US cancer patient groups responding to the ‘Corporate-Reputation’ survey during its last two months.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie
  • Boehringer Ingelheim
  • Eli Lilly
  • Ipsen
  • Merck KGaA/EMD Serono
  • Pierre Fabre
  • MORE

1 Executive summary
12 Cancer patient-group relationships with pharma, 2019
15 Industry-wide findings, 2019
20 Rankings of the 33 pharma companies, 2019 (v. 2018) among cancer patient groups familiar with the companies
35 Rankings of the 27 pharma companies, 2019 (v. 2018) among cancer patient groups that work with the companies
50 Profiles of the 33 companies, 2019 (v. 2018)

Appendices
I What cancer patient groups say on pharma(and how the industry can improve), 2019/2020
II Profiles of respondent cancer patient groups, 2019

As separate supplements:
III The views of 58 blood-cancer patient groups, 2019
IV The views of 75 breast-cancer patient groups, 2019
V The views of 29 lung-cancer patient groups, 2019
VI The views 22 ovarian-cancer patient groups, 2019
VII The views of 24 prostate-cancer patient groups, 2019
VIII The views of 25 rare-cancer patient groups, 2019

Tables and Charts

  • The key specialty areas of 2019’s respondent cancer patient groups
  • The corporate reputation of the pharmaceutical industry, 2019 v. 2018 (percentage of seven different types of respondent cancer patient groups stating “Excellent” or “Good”)  
  • How well seven different types of cancer patient groups assess the pharmaceutical industry to perform at various activities of importance to patients, 2019 (percentage of respondent cancer patient groups stating “Excellent” or “Good”)  
  • Whether six different types of cancer patient groups have relationships with individual pharmaceutical companies, 2019  
  • Companies ranking 1st for corporate reputation among six different types of cancer patient groups, 2019 (according to the respondent specialised cancer patient groups familiar with the company)
  • The rankings of 14 ‘big-pharma’ companies at corporate reputation, 2019 v. 2018 (according to respondent cancer patient groups familiar with the companies)  
  • The rankings of 14 ‘big-pharma’ companies at corporate reputation, 2019 v. 2018 (according to respondent cancer patient groups that work or partner with the companies)Cancer patient groups: familiarity, and partnerships, with pharma companies, 2019 (according to respondent cancer patient groups)
  • The types of working relationships that respondent cancer patient groups have with pharma companies, 2019  
  • The corporate reputation of the pharmaceutical industry, 2019 v. 2018 - compared with that of 8 other healthcare sectors (according to respondent cancer patient groups)  
  • The corporate reputation of the pharmaceutical industry, 2013-2019 (according to respondent cancer patient groups)  
  • The perceived effectiveness of the pharmaceutical industry at carrying out specific activities, 2019 v. 2018(according to respondent cancer patient groups)  
  • Perceptions of the efficacy of the pharmaceutical industry at various activities of importance to patient groups, 2019 v. previous years (according to respondent cancer patient groups)  
  • Rankings of 33 individual pharma companies, 2019 v. 2018 (according to respondent cancer patient groups familiar with the company)  
  • Rankings of 27 individual pharma companies, 2019 v. 2018 (according to respondent cancer patient groups that work or partner with the company)

Profiles of the 33 companies, 2019 v. 2018, charts and tables

  • Number of respondent cancer patient groups claiming familiarity with the company, 2019.
  • Number of respondent cancer patient groups saying that they had a working relationship with the company, 2019.
  • Profile of respondent cancer patient groups familiar with the company, 2019: country headquarters; specialties; geographic remit; and types of relationships.
  • Company scores among respondent cancer patient groups familiar with the company, and which work with the company, for each of the 12 indicators of corporate reputation, 2019. Percentage of the respondent cancer patient groups that work with the company, but which also work with other companies, 2019.
  • Overall rankings for the company according to respondent cancer patient groups familiar with the company, 2019 v. 2018.
  • Overall rankings for the company according to respondent cancer patient groups that work with the company, 2019 v. 2018.
  • Company rankings for each of the 12 indicators according to respondent cancer patient groups familiar, or working, with the company, 2019 v. 2018.
  • Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent cancer patient groups familiar with the company, 2019.
  • Snapshot view: where the company sits in the corporate tiers for each of the 12 indicators (in the higher, the middle, or the lower tier), as assessed by respondent cancer patient groups that work with the company, 2019.
  • The company’s Patient Corporate Reputation Indexes (PCRIs), 2015-2019 - selected indicators.
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Boehringer Ingelheim
  • Bristol Myers Squibb
  • Celgene*
  • Daiichi Sankyo
  • Eisai
  • Eli Lilly
  • Ferring
  • Gedeon Richter
  • Gilead Sciences/Kite Pharma
  • Grifols
  • GSK
  • Ipsen
  • Janssen
  • LEO Pharma
  • Menarini
  • Merck & Co/MSD
  • Merck KGaA/EMD Serono
  • Mundipharma
  • Novartis
  • Otsuka
  • Pfizer
  • Pierre Fabre
  • Roche/Genentech
  • Sandoz
  • Sanofi
  • Servier
  • Takeda/Shire
  • Teva

* Celgene has been included as a separate entity in the 2019 results because the company’s acquisition by Bristol Myers Squibb was only completed in November 2019, and the ‘Corporate-Reputation’ survey is intended to reflect the views of patient groups throughout 2019.

Note: Product cover images may vary from those shown
Adroll
adroll